ArticleBMC cancer2021
Upregulated NLGN1 predicts poor survival in colorectal cancer.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- BOMIFA: biologically informed multi-omics integration with graph contrastive learning for cancer prognosis in women.Briefings in bioinformatics · 2026Article
- Expression pattern, functional characteristics and prognostic significance of NLGN1 gene in nasopharyngeal carcinoma: a comprehensive multi-omics analysis.Discover oncology · 2026Article
- Pan-cancer analysis reveals AOC3 as a potential therapeutic biomarker for colorectal cancer.Discover oncology · 2025Article
- Gene Swin transformer: new deep learning method for colorectal cancer prognosis using transcriptomic data.Briefings in bioinformatics · 2025Article
- Exploring the tumor microenvironment of breast cancer to develop a prognostic model and predict immunotherapy responses.Scientific reports · 2025Article
- Understanding the impact of spatial immunophenotypes on the survival of endometrial cancer patients through the ProMisE classification.Cancer immunology, immunotherapy : CII · 2025Article
- Transcriptome Analysis of Transiently Reversible Cell Vacuolization Caused by Excessive Serum Concentration inBiology · 2024Article
- Early results of the integrative epigenomic-transcriptomic landscape of colorectal adenoma and cancer.World journal of gastrointestinal oncology · 2024Article
- Identification of glutamine metabolism-related gene signature to predict colorectal cancer prognosis.Journal of Cancer · 2024Article
- PriPath: identifying dysregulated pathways from differential gene expression via grouping, scoring, and modeling with an embedded feature selection approach.BMC bioinformatics · 2023Article
- An Overview of the Molecular Cues and Their Intracellular Signaling Shared by Cancer and the Nervous System: From Neurotransmitters to Synaptic Proteins, Anatomy of an All-Inclusive Cooperation.International journal of molecular sciences · 2022Review
- The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway.Journal of experimental & clinical cancer research : CR · 2022Article
- Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.Frontiers in oncology · 2022Article
- Cancer-associated fibroblast-related gene signatures predict survival and drug response in patients with colorectal cancer.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroligin1 (NLGN1) is a main component of excitatory glutamatergic synapses complex and is important for synapse assembly and function. The clinical value of NLGN1 in colorectal cancer (CRC) is not clear.
methodsWe obtained the expression data of 1143 CRC patients from 3 independent Gene Expression Omnibus (GEO) datasets (GSE32323, GSE24551, GSE39582) and The Cancer Genome Atlas (TCGA) to make the comparison of the NLGN1 expression level between CRC tissues and matched noncancerous tissues, and to evaluate its value in predicting survival of CRC patients. At the protein level, these results were further confirmed by immunohistochemical staining of 52 CRC samples in our own centre. Finally, the function of NLGN1 was explored by gene set enrichment analysis (GSEA).
resultsIncreased mRNA and protein levels of NLGN1 expression were associated with worse overall survival or recurrence-free survival in CRC patients from 2 GEO datasets, the TCGA database, and our cohort. In addition, multivariate regression analysis showed that NLGN1 was an independent poor prognostic factor of survival in patients with CRC in TCGA database (OR = 2.524, P = 0.010). Functional analysis revealed that NLGN1 was correlated with function involving the Hedgehog signaling pathway, mismatch repair process, and some material metabolism processes.
conclusionsThis study is the first to implicate and verify NLGN1 as a new poor prognostic marker for CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.